A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Multi-Center Study to Evaluate the Efficacy and Safety of Clazakizumab Subcutaneous Injection in Adults with Active Psoriatic Arthritis.

Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Multi-Center Study to Evaluate the Efficacy and Safety of Clazakizumab Subcutaneous Injection in Adults with Active Psoriatic Arthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2016

At a glance

  • Drugs Clazakizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Sponsors Alder Biopharmaceuticals; Bristol-Myers Squibb
  • Most Recent Events

    • 05 Apr 2016 Results published in the Arthritis and Rheumatology
    • 27 Jan 2015 Planned End Date changed from 1 Jan 2016 to 1 Jun 2015 as reported by ClinicalTrials.gov.
    • 15 Nov 2014 Top-line results published in an Alder BioPharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top